SK Biopharmaceuticals Co., Ltd.
326030
Pozycja w akcjach
#3730
SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the... SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the research, identification, and development of novel therapies for central nervous system (CNS) disorders. Their product portfolio features Cenobamate, indicated for the treatment of epilepsy, and Solriamfetol, which addresses excessive daytime sleepiness experienced in conditions like narcolepsy or obstructive sleep apnea. The company's robust clinical pipeline includes Carisbamate, currently in Phase 1b/2 trials for Lennox-Gastaut syndrome, and Relenopride, advancing through Phase 2 for a rare neurological disease. Additionally, they have several candidates in Phase 1 development: SKL13865 for attention deficit/hyperactivity disorder (ADHD), SKL20540 for schizophrenia, SKL-PSY for bipolar disorder, and SKL24741, another potential treatment for epilepsy. Founded in 2011, the company is headquartered in Seongnam, South Korea, and functions as a subsidiary of SK Inc.
Cena akcji
$56.51
Kapitalizacja rynkowa
$4.43B
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
-25.24%
Kraj
KR
Handel SK Biopharmaceuticals Co., Ltd. (326030)
Kategoria
Healthcare
Historia ceny akcji dla SK Biopharmaceuticals Co., Ltd. (326030)
Najwyższa cena zamknięcia: $51.70 dnia 2026-10-01
Najniższa cena zamknięcia: $157.85 dnia 2020-07-01
Najniższa cena zamknięcia: $157.85 dnia 2020-07-01
Historia cen akcji firmy SK Biopharmaceuticals Co., Ltd. od 2020 do 2026
Roczna wydajność ceny akcji
| Rok | Wydajność |
|---|---|
| 2026 (TTM) | -22.47% |
| 2025 | 24.61% |
| 2024 | 2.56% |
| 2023 | 25.24% |
| 2022 | -33.05% |
| 2021 | -47.19% |
| 2020 | 0.00% |
Cena akcji podobnych firm lub konkurencji
| Firma | Cena akcji | Zmiana 1r% | Kraj |
|---|---|---|---|
| $535.96 | 25.68% |
US
|
|
| $186.23 | 593.59% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $892.29 | 9.59% |
NL
|
